Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2012-06-01

Clinical Trial Update: Anti-psychotic Medication (Stable Dose) Weight Loss Study [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating an anti-psychotic medication for obesity was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Unspecified anti-psychotic medication

Snippet

Sponsor: Avera McKennan Hospital & University Health Center | Conditions: Obesity | Phase 2 | Status: WITHDRAWN